Stabilis

Ofloxacin



Noms commerciaux

Anzatax	Malaisie
Floxil	Mexique
Floxitril	Inde
Floxstat	Colombie, Equateur, Mexique
Istaflox	Mexique
Menefloks	Turquie
Oflocare	Pérou
Oflocet	Maroc, Portugal, Tunisie
Oflogyl	Vénézuela
Ofloxacin	Etats Unis d'Amérique
Ofloxacine	France
Ofloxin	Egypte
Ofloxol	Malaisie
Surnox	Espagne
Tabrin	Grèce
Tarivid	Allemagne, Arabie Saoudite, Autriche, Grande Bretagne, Hongrie, Irlande, Luxembourg, Norvège, Pays bas, Pologne, Portugal, Suisse, Turquie
Zanocin	Inde, Pologne
Zanovid	Inde
Zenflox	Inde

Stabilité des solutions

PVC		0,4 & 4 mg/ml	-20°C		182			444
PVC		0,4 & 4 mg/ml	24°C		3			444
PVC		0,4 & 4 mg/ml	5°C		14			444
PVC		0,4 & 4 mg/ml	-20°C		182			444
PVC		0,4 & 4 mg/ml	24°C		3			444
PVC		0,4 & 4 mg/ml	5°C		14			444
PVC	Δ® P1 ◆1.5	0,025 mg/ml	25°C		7			2155
PVC	Δ® P1 ◆1.5	0,025 mg/ml	37°C		48			2155

PVC	Δ® P1 ◆1.5	0,025 mg/ml	4°C		14				2155
PVC	Δ® P1 ◆4.25	0,025 mg/ml	25°C		7				2155
PVC	Δ® P1 ◆4.25	0,025 mg/ml	37°C		48				2155
PVC	Δ® P1 ◆4.25	0,025 mg/ml	4°C		14				2155

Stabilité en mélange

		2 mg/ml	25°C	?	Amoxicillin sodium : 10 mg/ml	48	889
		2 mg/ml	25°C	?	Amoxicillin sodium / clavulanic acid : 12 mg/ml	48	889
		2 mg/ml	25°C	?	Tobramycin sulfate : 0,8 mg/ml	48	889
		2 mg/ml	25°C	?	Gentamicin sulfate : 0,8 mg/ml	48	889
		2 mg/ml	25°C	?	Clindamycin phosphate : 6 mg/ml	48	889
		2 mg/ml	25°C	?	Vancomycin hydrochloride : 5 mg/ml	48	889
		2 mg/ml	25°C	?	Ceftazidime : 10 mg/ml	48	889
		2 mg/ml	25°C	?	Piperacillin sodium : 20 mg/ml	48	889
POF		4 mg/ml	23°C		Linezolid : 2 mg/ml	7	1668
POF		4 mg/ml	4°C		Linezolid : 2 mg/ml	7	1668
?		2,2 mg/ml	25°C	?	Ampicillin sodium : 21 mg/ml	2	1481

Compatibilités

		Ofloxacin : 2 mg/ml Amoxicillin sodium : 10 mg/ml		889
		Ofloxacin : 2 mg/ml Amoxicillin sodium / clavulanic acid : 12 mg/ml		889
		Ofloxacin : 4 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	◆	921
		Ofloxacin : 4 mg/ml Bivalirudin : 5 mg/ml	◆	1713
		Ofloxacin : 5 mg/ml Bumetanide : 0.5 mg/ml		2139
		Ofloxacin Ceftazidime		3883
		Ofloxacin : 2 mg/ml Ceftazidime : 10 mg/ml		889
		Ofloxacin : 4 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	◆	299

		Ofloxacin : 2 mg/ml Clindamycin phosphate : 6 mg/ml	∅	889
		Ofloxacin : 4 mg/ml Dexmedetomidine : 4 µg/ml	▲	1712
		Ofloxacin : 4 mg/ml Docetaxel : 0.9 mg/ml	◆	1754
		Ofloxacin : 4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	◆	251
		Ofloxacin : 4 mg/ml Etoposide phosphate : 5 mg/ml	◆	1410
		Ofloxacin : 4 mg/ml Gemcitabine hydrochloride : 10 mg/ml	▲	1423
		Ofloxacin : 4 mg/ml		301
		Ofloxacin : 2 mg/ml Flucloxacillin sodium : 10 mg/ml	∅	889
		Ofloxacin : 2 mg/ml Gentamicin sulfate : 0,8 mg/ml	∅	889
		Ofloxacin : 4 mg/ml Granisetron hydrochloride : 0.05 mg/ml	◆	182
		Ofloxacin Heparin sodium		3562
		Ofloxacin : 4 mg/ml Hetastarch : 60 mg/ml		1721
		Ofloxacin : 4 mg/ml Linezolid : 2 mg/ml	∅	1668
		Ofloxacin : 2 mg/ml Tobramycin sulfate : 0,8 mg/ml	∅	889
		Ofloxacin : 4 mg/ml		1415
		Ofloxacin : 4 mg/ml Lansoprazole : 0.55 mg/ml	▲	1625
		Ofloxacin : 4 mg/ml Linezolid : 2 mg/ml	∅	1925
		Ofloxacin : 2 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Ofloxacin : 2 mg/ml Piperacillin sodium : 20 mg/ml	∅	889
		Ofloxacin : 4 mg/ml Propofol : 10 mg/ml	∅	300
		Ofloxacin : 4 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
		Ofloxacin : 4 mg/ml Thiotepa : 1 mg/ml	◆	249
		Ofloxacin : 2 mg/ml Vancomycin hydrochloride : 5 mg/ml	∅	889

Voie d'administration

Bibliographie

	Type	Source
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
444	Revue	Bornstein M, Kao SH, Mercorelli M, Verma S. Stability of an ofloxacin injection in various infusion fluids. Am J Hosp Pharm 1992 ; 49: 2756-2760.
889	Revue	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.

1481	Revue	Messerschmidt W. Kompatibilität von ofloxacin mit ampicillin. Krankenhauspharmazie 1994 ; 9: 337-340.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1668	Revue	Zhang Y, Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three quinolone antibiotics. Ann Pharmacotherapy 2000 ; 34: 996-1001.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2139	Revue	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug's administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2155	Revue	Battista C, Kane MP, Moon DG, Bailie GR. Stability of ofloxacin in peritoneal dialysis solutions. Perit Dial Int 1995 ; 15: 72-74.
3562	Laboratoire	Ofloxacin (Tarivid®) - Summary of Product Characteristics Sanofi 2014
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016

Dictionnaire

	Antibiotique
	Noms commerciaux
	Contenant
	Concentration
	Conservation
	Biosimilaire
	Bibliographie
	Eau pour préparation injectable
	Jour
	Dianéal® PD1 1.5% glucose (Baxter)
	Dianéal® PD1 4.25% glucose (Baxter)
	Solvant
	Verre
?	Non précisée
?	Non précisé
	Compatible
	Incompatible
	Incompatibilité non précisée
	Turbidité immédiate
	Précipitation en 7 heures
	Nutrition parentérale (mélange ternaire)
	Perfusion intraveineuse
	Dictionnaire

	Injectable
	Stabilité des solutions
	Molécule
	Température
	Durée de stabilité
	Données conflictuelles
PVC	Polyvinyl chlorure
	A l'abri de la lumière
	NaCl 0,9% ou glucose 5%
	Heure
	Stabilité en mélange
	Molécule
∅	Aucun
POF	Polyolefine
	Compatibilités
	Précipitation immédiate
	Glucose 5%
	Chlorure de sodium 0,9%
	Nutrition parentérale (mélange binaire)
	Solvant spécifique
	Voie d'administration
	Bibliographie